Company HST5040 Patients Pipeline Platform News Careers Focus on Patients At HemoShear we are driven to apply our scientific insights to develop medicines that improve the lives of patients with rare metabolic diseases. We are committed to understanding and helping to meet the needs of patients and their families. New MMA and PA Treatments Needed We are currently focused on developing a treatment for methylmalonic acidemia (MMA) and propionic acidemia (PA). These rare genetic diseases are caused by inherited metabolic defects that result in the build-up of harmful toxins that can lead to severe organ damage, seizures, developmental deficits, and premature death. Although usually diagnosed soon after birth, there are currently no medical treatments for MMA or PA that improve quality of life or extend lifespan. Patients are treated by managing symptoms and following very restrictive diets. Clinical Study SIGN UP TO RECEIVE INFO + The HERO Study HemoShear is conducting the HERO (HElp Reduce Organic Acids) clinical study to assess our experimental drug HST5040 in patients with MMA and PA. HERO is being conducted with patients aged 2 and older at select leading children’s hospitals around the United States. Information about HERO can be found on the study website or on Clinicaltrial.gov. If there is a study site located near you, then you can speak with your physician or contact the site about participating. Please sign up if you would like to receive information from HemoShear about our clinical trial or other company developments. HERO STUDY LOCATIONS The clinical study is being conducted at 10 centers in the United States. If there is a study site located near you, then you can speak with your physician or find site contact information on Clinicaltrial.gov. Learn how methylmalonic acidemia and propionic acidemia affect the body and about experimental drug HST5040 being developed to treat these rare diseases. PLAY VIDEO Hemoshear Policy on Expanded Access to Investigational Drugs If you have any questions regarding this policy, please contact: patients@hemoshear.com. We expect to respond to inquiries within 7 business days. HemoShear Therapeutics is committed to developing therapies that improve the lives of patients with rare genetic disorders with high unmet need, such as methylmalonic acidemia (MMA) and propionic acidemia (PA). We are working with a sense of urgency as we focus on designing and conducting clinical trials to assess safety and efficacy of our oral drug candidate HST5040 for patients with MMA and PA. We are dedicated to expeditiously developing potential new therapies and believe that the most effective strategy for making them widely available to patients around the world is to maintain our focus on conducting the necessary research and development, including efficient enrollment and completion of the clinical trials required to support global regulatory approvals. Clinical trials are required to establish whether an investigational medical product is safe and effective, and participants in clinical trials play a critical role in informing the understanding and treatment of serious diseases. We believe that participation in one of our clinical trials is the most appropriate way to access investigational drugs like HST5040 and we are not currently providing the drug for expanded access. Stay in Touch We would like to keep patients and families informed of our progress. Please sign up if you would like to receive information via email from HemoShear about our clinical trial or other company developments. If you have any questions, please email us at patients@hemoshear.com SIGN UP + Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact